Main Menu

Treatment of B-cell acute lymphoblastic leukemia (ALL) and lymphoma using chimeric antigen receptors (CARs) targeting B-cell surface protein CD19 has demonstrated impressive clinical results in children and young adults. Despite the promising results from CD19 CAR therapy, up to 40% of patients, who initially achieve remission, eventually relapse. Relapse or non-response to CD19-directed CAR therapy may be due to low or diminished CD19 expression. Such patients would be predicted to benefit from CAR therapies targeting other B-cell surface proteins, such as CD22.

HCC is the most frequent malignant tumor in the liver and the third leading cause of cancer death worldwide.  A progressive sequence of somatic mutations and epigenetic changes of oncogenes or tumor suppressor genes are believed to cause tumor development. However, high genomic instability in tumors causes the accumulation of genomic aberrations that do not contribute to tumor progression. Therefore, it is important to distinguish between ''driver'' mutations that are functionally important and ''passenger'' mutations that do not provide a selective advantage to the tumor cells.

Chimeric antigen receptors (CARs) combine an antibody-based binding domain (and single chain fragment variable region, scFv) with T cell receptor signaling domains (CD3 zeta with a costimulatory domain, typically CD28 or 41BB). When T cells express CARs, they are activated in a major histocompatibility complex- (MHC) independent manner to kill tumor cells expressing the target to which the scFv binds.  CAR T cells targeting the B cell antigen CD19 have resulted in remissions in 60-80% of patients with pre-B cell precursor acute lymphoblastic leukemia (BCP-ALL).

In the United States alone, one of four cancer deaths occur from lung cancer and there are over 8 million individuals considered to be at high-risk due to cigarette smoking and other behaviors. It's well known that early detection of cancer significantly improves survival of this disease, however a lack of lung cancer screenings and analysis precludes fast results at a low cost.

The National Cancer Institute's Urologic Oncology Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the use of Tempol to target HIF-2a in cancer.

Summary:

The National Institute on Aging (NIA) seeks research co-development partners and/or licensees for the pre-clinical and clinical development of the compounds as anti-inflammatory therapeutics for systemic degenerative and neurodegenerative disorders.

Selective A3AR agonists are sought as potential agents for treating inflammatory diseases,
chronic pain, cancer and non-alcoholic steatohepatitis (NASH). NIDDK investigators have invented 
new chemical composition as positive allosteric modulators (PAMs) of the A3AR. These chemical 
compounds contain sterically constrained, bridged modifications and cycloalkyl rings of various 
sizes, as well as modifications of the 4-arylamino group. The compounds have added 

GSD-Ia is an inherited disorder of metabolism associated with life-threatening hypoglycemia, hepatic malignancy, and renal failure caused by the deficiency of glucose-6-phosphatase-alpha (G6Pase-alpha or G6PC). Current therapy, which primarily consists of dietary modification, fails to prevent long-term complications in many patients, including growth failure, gout, pulmonary hypertension, renal dysfunction, osteoporosis, and hepatocellular adenomas (HCA).

Crouch gait is a common disorder in pediatric cerebral palsy (CP). Effective treatment of crouch during childhood is critical to maintain mobility into adulthood. Current interventions do not alleviate crouch gait long-term for most patients. This technology relates to a powered exoskeleton designed for gait assistance. The powered assistance may provide a physical therapy-type intervention to improve and maintain mobility.  

Multiparametric MRI improves image detail and prostate cancer detection rates compared to standard MRI. Computer aided diagnostics (CAD) used in combination with multiparametric MRI images may further improve prostate cancer detection and visualization. The technology, developed by researchers at the National Institutes of Health Clinical Center (NIHCC), is an automated CAD system for use in processing and visualizing prostate lesions on multiparametric MRI images.